Showing 1 to 12 of 13 results
Trump Threatens 250% Tariff on Australian Pharmaceuticals
President Trump threatened a 250% tariff on Australian pharmaceuticals, impacting \$2.1 billion in 2024 exports; this follows his ultimatum to 17 pharmaceutical companies to lower US prices, which are almost four times higher than in Australia due to the Pharmaceutical Benefits Scheme (PBS), a syste...
Trump Threatens 250% Tariff on Australian Pharmaceuticals
President Trump threatened a 250% tariff on Australian pharmaceuticals, impacting \$2.1 billion in 2024 exports; this follows his ultimatum to 17 pharmaceutical companies to lower US prices, which are almost four times higher than in Australia due to the Pharmaceutical Benefits Scheme (PBS), a syste...
Progress
48% Bias Score
AstraZeneca's \$37 Billion US Investment Amid Tariff Fears
AstraZeneca plans to invest \$37 billion in the US, creating tens of thousands of jobs, amid President Trump's threatened pharmaceutical tariffs, raising concerns about the company potentially moving its primary stock market listing from London to New York.
AstraZeneca's \$37 Billion US Investment Amid Tariff Fears
AstraZeneca plans to invest \$37 billion in the US, creating tens of thousands of jobs, amid President Trump's threatened pharmaceutical tariffs, raising concerns about the company potentially moving its primary stock market listing from London to New York.
Progress
60% Bias Score
Pharmacists Fear Drug Tariffs Will Worsen Shortages, Raise Prices
President Trump's proposed tariffs on imported pharmaceuticals are causing widespread concern among pharmacists, who worry that the tariffs will exacerbate existing drug shortages and drive up prices, particularly for independent pharmacies operating on razor-thin margins.
Pharmacists Fear Drug Tariffs Will Worsen Shortages, Raise Prices
President Trump's proposed tariffs on imported pharmaceuticals are causing widespread concern among pharmacists, who worry that the tariffs will exacerbate existing drug shortages and drive up prices, particularly for independent pharmacies operating on razor-thin margins.
Progress
48% Bias Score
Trump's Pharmaceutical Tariffs: Higher Prices, Shortages, Uncertain Production Boost
President Trump's announcement of major tariffs on pharmaceutical imports aims to boost domestic drug manufacturing but may instead increase drug prices and shortages, impacting patient access to essential medicines, with any increase in US production years away.
Trump's Pharmaceutical Tariffs: Higher Prices, Shortages, Uncertain Production Boost
President Trump's announcement of major tariffs on pharmaceutical imports aims to boost domestic drug manufacturing but may instead increase drug prices and shortages, impacting patient access to essential medicines, with any increase in US production years away.
Progress
52% Bias Score
Trump's Tariff Threat Wipes £14 Billion Off UK Drugmakers
President Trump's threat of US tariffs on pharmaceutical imports caused a £14 billion loss in market value for AstraZeneca and GSK, highlighting the reliance of British drugmakers on US sales and sparking concerns about global supply chain disruptions and potential public health risks due to planned...
Trump's Tariff Threat Wipes £14 Billion Off UK Drugmakers
President Trump's threat of US tariffs on pharmaceutical imports caused a £14 billion loss in market value for AstraZeneca and GSK, highlighting the reliance of British drugmakers on US sales and sparking concerns about global supply chain disruptions and potential public health risks due to planned...
Progress
40% Bias Score
US and EU Avert Pharmaceutical Tariff Clash, But Concerns Remain
The US and EU avoided imposing tariffs on pharmaceutical products, averting a potential crisis in a sector where the US imported \$127 billion worth of goods from the EU in 2024, although concerns remain about future trade disputes.
US and EU Avert Pharmaceutical Tariff Clash, But Concerns Remain
The US and EU avoided imposing tariffs on pharmaceutical products, averting a potential crisis in a sector where the US imported \$127 billion worth of goods from the EU in 2024, although concerns remain about future trade disputes.
Progress
40% Bias Score
Pharma Companies Pledge Billions in US Manufacturing Amid Tariff Threats
Faced with potential tariffs, major US pharmaceutical companies announced over \$250 billion in domestic manufacturing expansions; however, experts doubt this will significantly reduce US reliance on foreign drug sources or lower consumer costs.
Pharma Companies Pledge Billions in US Manufacturing Amid Tariff Threats
Faced with potential tariffs, major US pharmaceutical companies announced over \$250 billion in domestic manufacturing expansions; however, experts doubt this will significantly reduce US reliance on foreign drug sources or lower consumer costs.
Progress
44% Bias Score
US Pharmaceutical Tariffs Threaten Drug Shortages and Higher Prices
The imminent expiration of a 90-day pause on U.S. import duties threatens to impose tariffs on imported pharmaceuticals, potentially violating WTO rules, causing higher prices for brand-name drugs and exacerbating existing generic drug shortages, especially of antibiotics and chemotherapy treatments...
US Pharmaceutical Tariffs Threaten Drug Shortages and Higher Prices
The imminent expiration of a 90-day pause on U.S. import duties threatens to impose tariffs on imported pharmaceuticals, potentially violating WTO rules, causing higher prices for brand-name drugs and exacerbating existing generic drug shortages, especially of antibiotics and chemotherapy treatments...
Progress
48% Bias Score
Trump's Pharmaceutical Tariffs Threaten Drug Shortages
President Trump's planned tariffs on pharmaceutical imports are raising concerns about drug shortages and price increases, impacting generic drug manufacturers significantly, with a 270-day investigation underway to assess national security implications.
Trump's Pharmaceutical Tariffs Threaten Drug Shortages
President Trump's planned tariffs on pharmaceutical imports are raising concerns about drug shortages and price increases, impacting generic drug manufacturers significantly, with a 270-day investigation underway to assess national security implications.
Progress
48% Bias Score
Trump's Pharmaceutical Tariffs: Higher Prices, Shortages, and Uncertain Domestic Production
President Trump announced major tariffs on pharmaceutical imports, expected to increase drug prices and worsen shortages, while the impact on domestic manufacturing remains debated and years away.
Trump's Pharmaceutical Tariffs: Higher Prices, Shortages, and Uncertain Domestic Production
President Trump announced major tariffs on pharmaceutical imports, expected to increase drug prices and worsen shortages, while the impact on domestic manufacturing remains debated and years away.
Progress
48% Bias Score
Trump's Tariffs Set to Hike Drug Prices
President Trump's new tariffs will likely increase prices for many drugs, potentially adding $750 million to costs from Canadian imports alone, with further increases if extended to other countries; the U.S. relies heavily on imports for active pharmaceutical ingredients.
Trump's Tariffs Set to Hike Drug Prices
President Trump's new tariffs will likely increase prices for many drugs, potentially adding $750 million to costs from Canadian imports alone, with further increases if extended to other countries; the U.S. relies heavily on imports for active pharmaceutical ingredients.
Progress
52% Bias Score
US-EU Pharmaceutical Tariff Dispute: Temporary Reprieve, Long-Term Concerns
The pharmaceutical sector escaped US tariffs for now, but the EU remains wary due to US policies encouraging relocation of manufacturing to the EU, primarily in Ireland, creating significant economic dependence and potentially long-term consequences.
US-EU Pharmaceutical Tariff Dispute: Temporary Reprieve, Long-Term Concerns
The pharmaceutical sector escaped US tariffs for now, but the EU remains wary due to US policies encouraging relocation of manufacturing to the EU, primarily in Ireland, creating significant economic dependence and potentially long-term consequences.
Progress
36% Bias Score
Showing 1 to 12 of 13 results